SynthesisMedicine2026
Prognostic and clinicopathological significance of CD133 in patients with hepatocellular carcinoma: A meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis was conducted to investigate whether CD133 could be used as a biomarker to predict prognosis in hepatocellular carcinoma patients.
methodsWe systematically retrieved relevant studies from these databases as of February 2026. Odds ratios and their 95% confidence intervals were used to estimate the association between CD133 expression and clinicopathological features. The associations between CD133 and survival outcomes, including overall survival (OS), disease-free survival, and recurrence-free survival, were estimated by hazard ratios and 95% confidence intervals.
resultsA total of 25 publications were included, involving 3278 patients. CD133 was highly expressed in liver cancer tissues (P < .05). Also, CD133 expression was associated with tumor size, tumor node metastasis stage, and tumor differentiation (P < .05). CD133-positive expression had shorter OS, disease-free survival, and recurrence-free survival than those with CD133-negative expression (P < .05).
conclusionThis meta-analysis suggests that CD133 is a potential biomarker for predicting poor survival in Asian hepatocellular carcinoma patients, especially for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.